aTYR PHARMA (ATYR) Net Equity Issued and Repurchased (2014 - 2025)

aTYR PHARMA (ATYR) has 12 years of Net Equity Issued and Repurchased data on file, last reported at $29.7 million in Q3 2025.

• Quarterly Net Equity Issued and Repurchased rose 29600.0% year-over-year to $29.7 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $66.4 million (up 64.76% YoY) and the FY2025 annual result came in at $66.4 million, up 64.76% from the prior year.
• Net Equity Issued and Repurchased improved to $29.7 million in Q3 2025, from $17.9 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $65.4 million in Q3 2021 to a low of -$65.4 million in Q4 2021.
• A 5-year average of $9.0 million and a median of $7.0 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2021 — Net Equity Issued and Repurchased plunged 1776.92% — and 2025, when it jumped 218504.65%.
• Tracing ATYR's Net Equity Issued and Repurchased over 5 years: stood at -$65.4 million in 2021, then soared by 103.82% to $2.5 million in 2022, then soared by 144.0% to $6.1 million in 2023, then jumped by 209.84% to $18.9 million in 2024, then soared by 57.14% to $29.7 million in 2025.
• The last three Net Equity Issued and Repurchased figures came in at $29.7 million (Q3 2025), $17.9 million (Q2 2025), and $18.8 million (Q1 2025), per Business Quant data.